Vorinostat

伏立诺他

Report date: 2025/10/30 17:39:22
NMEFirst In Class

Base Information

Drug NameVorinostat
Drug Alias NameSuberoylanilide Hydroxamic Acid沃诺司他沃雷诺司Vorinostatum伏瑞斯特 +[13] 
ClassificationSmall molecules
Mechanisms of ActionHistone deacetylase 2 inhibitorsHistone deacetylase 6 inhibitorsHistone deacetylase 3 inhibitors +[4] 
TargetsHistone deacetylase 2Histone deacetylase 1Histone deacetylase 3 +[4] 
Therapy Area/IndicationsUveal melanomaChronic eosinophilic leukemia (CEL)Medullary thyroid cancer (MTC) +[107] 
Global Approved IndicationsLymphoma, T-Cell, Cutaneous
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2006/10/06
Country/TerritoryCanadaUnited StatesSingapore +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPending
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe Netherlands Cancer InstituteMerck Sharp & Dohme CorpNational Cancer Institute +[6] 
Inactive CompaniesDana-Farber Cancer InstituteUniversity Of California San FranciscoEunice Kennedy Shriver National Institute Of Child Health And Human Development +[22] 
Active IndicationsUveal melanomaCrohn DiseaseSkin Neoplasms +[14] 
Inactive IndicationsChronic eosinophilic leukemia (CEL)Medullary thyroid cancer (MTC)Brain metastases +[93] 

Other Information

ATC CodeL01XH01
Related LinksWikipediaDrugBankKEGG